Published in

Hindawi, BioMed Research International, (2018), p. 1-7, 2018

DOI: 10.1155/2018/9056173

Links

Tools

Export citation

Search in Google Scholar

Prospects of IL-2 in Cancer Immunotherapy

Journal article published in 2018 by Hani Choudhry ORCID, Nawal Helmi ORCID, Wesam H. Abdulaal ORCID, Mustafa Zeyadi, Mazin A. Zamzami, Wei Wu, Maged Mostafa Mahmoud, Mohiuddin Khan Warsi, Mahmood Rasool ORCID, Mohammad S. Jamal ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

IL-2 is a powerful immune growth factor and it plays important role in sustaining T cell response. The potential of IL-2 in expanding T cells without loss of functionality has led to its early use in cancer immunotherapy. IL-2 has been reported to induce complete and durable regressions in cancer patients but immune related adverse effects have been reported (irAE). The present review discusses the prospects of IL-2 in immunotherapy for cancer.